Immutep (IMMP) has released an update.
Immutep has announced encouraging Phase IIb trial results for its novel combination of eftilagimod alfa with KEYTRUDA in treating head and neck cancer, showing improved overall response rates across all levels of PD-L1 expression. The company plans to discuss future regulatory pathways and will present more detailed clinical data in the second half of 2024. These findings could potentially expand the patient population benefiting from anti-PD-1 therapies.
For further insights into IMMP stock, check out TipRanks’ Stock Analysis page.
